Diagnosis and treatment of ovarian tumors

Ovarian tumors encompass a heterogeneous group of neoplasms that arise from ovarian tissues of different embryologic origins. They range from physiologic functional cysts to benign neoplasms and aggressive malignant cancers. Because many ovarian tumors are asymptomatic in early stages and because symptoms—when present—are frequently nonspecific, timely diagnosis can be challenging. Early identification and appropriate management are critical to optimize outcomes, preserve fertility when possible, and reduce morbidity from complications such as torsion, rupture, hemorrhage, and progression of malignant disease.

This article reviews the epidemiology, classification, clinical presentation, diagnostic evaluation, staging, and contemporary management strategies for ovarian tumors, emphasizing evidence-based guidance and the roles of conservative, surgical, and medical therapies.

Epidemiology and risk factors

Ovarian masses are commonly identified across the lifespan. Functional ovarian cysts are frequent in reproductive-age women and are usually benign and self-limited.
The incidence of ovarian cancer is lower than that of benign ovarian masses but carries substantially greater morbidity and mortality because many cases are diagnosed at an advanced stage.
Established risk factors for epithelial ovarian carcinoma include increasing age (peak incidence in postmenopausal women), family history of ovarian or breast cancer, and pathogenic variants in BRCA1, BRCA2, and mismatch repair genes (Lynch syndrome). Protective factors include combined oral contraceptive use, parity, and breastfeeding.
Germ cell tumors and sex cord-stromal tumors are more common in adolescents and young adults relative to epithelial cancers.

(See guidance from professional bodies for population-specific risk and screening recommendations.) [ACOG], [NIH].

Pathology and classification

Ovarian tumors are categorized based on their presumed cell of origin:

Functional cysts: follicular cysts, corpus luteum cysts — physiologic and commonly regress spontaneously.
Epithelial tumors: serous cystadenomas/cystadenocarcinomas, mucinous tumors, endometrioid, clear cell — most common group of ovarian malignancies in adults.
Germ cell tumors: mature cystic teratoma (dermoid), dysgerminoma, yolk sac tumor, embryonal carcinoma — predominate in adolescents and young women.
Sex cord–stromal tumors: granulosa cell tumor, fibrothecoma, Sertoli–Leydig cell tumor — may produce hormones (estrogen or androgen).
Metastatic tumors: tumors that spread to the ovary from other primary sites (e.g., Krukenberg tumors from gastrointestinal tract).

Mature cystic teratomas (dermoid cysts) are among the most common benign neoplasms in adolescents and young adults and are frequently encountered as incidental adnexal masses.

Clinical presentation

Asymptomatic: The majority of ovarian tumors, particularly small benign lesions, are asymptomatic and are discovered incidentally during pelvic examination or imaging performed for other indications.
Nonspecific pelvic or abdominal symptoms: pelvic pressure or fullness, abdominal distension, early satiety, urinary frequency, constipation, or intermittent pelvic pain.
Menstrual irregularities: may be associated with hormonally active tumors (e.g., granulosa cell tumors produce estrogen; Sertoli–Leydig tumors may cause virilization).
Acute presentations: sudden, severe lower abdominal pain may indicate ovarian torsion, tumor rupture, or hemorrhage into a cyst. Such presentations can mimic surgical emergencies like appendicitis or ectopic pregnancy (pregnancy testing is mandatory in reproductive-age patients).

Because symptoms are nonspecific and overlap with common benign conditions, a systematic diagnostic approach is necessary to distinguish benign from potentially malignant lesions and to identify emergencies requiring immediate intervention.

Differential diagnosis

Common considerations for adnexal or lower abdominal masses include:

Functional ovarian cysts (follicular or corpus luteum)
Ectopic pregnancy (must be excluded with pregnancy testing)
Pelvic inflammatory disease and tubo-ovarian abscess
Uterine fibroids (subserosal)
Gastrointestinal sources (appendicitis, diverticulitis)
Urinary tract pathology (complex cysts, hydronephrosis)

Clinical history, pregnancy testing, imaging, and laboratory studies help refine the differential diagnosis.

Diagnostic evaluation

A structured evaluation combines history, physical examination, serum testing, imaging, and in selected cases invasive procedures.

History and physical examination

Elicit symptom onset, duration, character of pain, menstrual history, contraception use, fertility desires, prior pelvic surgery, family history of breast or ovarian cancer, and systemic symptoms (weight loss, anorexia).
Physical exam includes a general abdominal and pelvic examination. Bimanual pelvic examination may detect adnexal masses, their size, mobility, and tenderness. Findings are often limited by habitus and patient comfort and are supplemented by imaging.

Pregnancy test

A serum or urine β-hCG test is essential in any woman of reproductive potential to exclude ectopic pregnancy before imaging or surgical planning.

Serum tumor markers

Tumor markers are adjunctive tests; none are sufficiently sensitive or specific to be used alone for diagnosis or screening of ovarian tumors. Their utility is greater in risk stratification and monitoring treatment response.

CA-125: elevated in many epithelial ovarian cancers, particularly high-grade serous carcinoma. Sensitivity and specificity are limited; CA-125 is more likely to be elevated in postmenopausal women with epithelial malignancy. It can be elevated in benign conditions (endometriosis, menstruation, pelvic inflammation). Not recommended as a screening test in the general population.
hCG, α-fetoprotein (AFP), lactate dehydrogenase (LDH): useful in suspected germ cell tumors.
Inhibin A/B and anti-Müllerian hormone (AMH): may be useful for sex cord–stromal tumors.
HE4 and risk algorithms: HE4 combined with CA-125 and risk models (e.g., Risk of Ovarian Malignancy Algorithm — ROMA) can improve preoperative assessment, particularly in postmenopausal women.

References: ACOG and oncology guidelines provide algorithms for using tumor markers in diagnostic workup and follow-up [ACOG], [NIH].

Imaging

Imaging guides diagnosis, characterizes lesions, and informs surgical planning.

Transvaginal ultrasound (TVUS) is the imaging modality of choice for adnexal masses. It provides high resolution of adnexal structures and can typically distinguish simple cystic lesions from complex or solid components. Doppler ultrasound can assess vascular flow and may aid in evaluating risk of malignancy and recognizing torsion (reduced or absent flow is suggestive but not definitive).
Transabdominal ultrasound can complement TVUS for large masses or when transvaginal examination is not feasible.
Ultrasound-based risk models (International Ovarian Tumor Analysis — IOTA Simple Rules, IOTA ADNEX model) assist in distinguishing benign from malignant adnexal masses and guide referral to gynecologic oncology when appropriate.
MRI of the pelvis: used as a problem-solving tool when ultrasound is inconclusive. MRI provides better soft-tissue contrast and characterizes tissue type (fat, hemorrhage, solid components) and can be particularly helpful for adnexal mass characterization prior to surgery.
CT scan: used for staging and detecting metastasis in cases of suspected malignancy or to evaluate acute complications such as rupture or hemorrhage. CT is not first-line for primary characterization of ovarian masses.
PET/CT: limited utility for primary diagnosis; used selectively in staging or recurrent disease assessment.

Clinical practice guidelines recommend transvaginal ultrasound as the first-line imaging modality for adnexal lesions, with MRI reserved for indeterminate cases or to aid preoperative planning [Mayo Clinic], [Cleveland Clinic].

Minimally invasive diagnostic procedures

Diagnostic laparoscopy: considered when imaging and serum markers are indeterminate, when tissue diagnosis is required, or when conservative management fails. Laparoscopy allows direct visualization, biopsy, and resection of lesions with histopathologic diagnosis. Laparoscopy is also the preferred surgical approach for many benign adnexal pathologies and for staging early malignant disease in selected patients.
Image-guided aspiration of ovarian cysts: generally discouraged as a routine diagnostic or therapeutic approach because of high recurrence rates, risk of infection, and potential for tumor dissemination if the lesion is malignant.

Staging and histopathology

When a malignant ovarian tumor is identified, histopathologic classification and staging determine prognosis and therapy.

FIGO staging system for ovarian cancer is used to classify disease based on surgical and pathologic findings (confined to ovaries vs. spread to peritoneum, lymph nodes, and distant organs).
Proper staging typically requires comprehensive surgical exploration, peritoneal cytology, omentectomy, peritoneal biopsies, and assessment of nodal basins in selected situations.
Histologic subtype (serous, mucinous, endometrioid, clear cell, germ cell, sex cord–stromal) and grade substantially influence management and prognosis.

Prompt referral to a gynecologic oncologist is recommended when malignancy is suspected or confirmed, as specialized surgical staging and cytoreductive procedures improve outcomes [ACOG], [NCI].

Management principles

Treatment is individualized according to the lesion type (functional vs. neoplastic), suspicion for malignancy, patient age, comorbidities, and fertility desires.

Management of functional ovarian cysts

Observation: Most functional cysts in premenopausal women are managed expectantly with follow-up ultrasound in 6–12 weeks, as many resolve spontaneously.
Intervention: Indications for surgery include persistent cysts, symptomatic lesions, large size (often >5–10 cm depending on context), complex or solid features on imaging, or suspicion for malignancy. Emergency intervention is required for torsion, rupture with hemodynamic instability, or uncontrolled hemorrhage.

Management of benign adnexal tumors

Surgical options: cystectomy (removal of cyst while preserving ovarian tissue) is preferred for benign cysts in women desiring fertility. Oophorectomy or salpingo-oophorectomy may be necessary for large or extensively involved ovaries, suspected malignancy, or in postmenopausal patients where preservation is less critical.
Minimally invasive surgery (laparoscopy) offers benefits of reduced postoperative pain, shorter hospital stay, and faster recovery compared with laparotomy for appropriately selected benign lesions.
Intraoperative precautions: avoid spillage of cyst contents in cases where a malignant tumor cannot be excluded; if spillage occurs and malignancy is subsequently diagnosed, upstaging can result.

Management of ovarian torsion

Ovarian torsion is a surgical emergency. Prompt detorsion and salvage of viable ovarian tissue is the goal, particularly in children and those desiring fertility.
Historically, oophorectomy was often performed when the ovary appeared ischemic; contemporary practice favors detorsion whenever possible because even ischemic-appearing ovaries may regain function.
If a necrotic and nonviable ovary is present or if malignancy is suspected, oophorectomy may be indicated.

Management of malignant ovarian tumors

General principles:

Multimodality therapy is standard for ovarian cancer, combining surgery and systemic therapy. Management is guided by histology, stage, patient performance status, and genomic factors.
Optimal cytoreductive surgery (maximal tumor debulking) is associated with improved survival in advanced epithelial ovarian cancer. A gynecologic oncologist should perform primary cytoreductive surgery when feasible.
Fertility-sparing surgery (unilateral salpingo-oophorectomy with careful staging) may be considered for select patients with early-stage germ cell tumors or low-grade epithelial tumors who desire future fertility, after detailed counseling and staging.

Surgical management:

Early-stage epithelial ovarian cancer: comprehensive staging including peritoneal washings, excision of all visible disease, omentectomy, peritoneal biopsies, and selective lymphadenectomy as indicated.
Advanced disease: cytoreductive surgery aimed at achieving no gross residual disease, which may include multivisceral resections.

Systemic therapy:

First-line chemotherapy for most advanced epithelial ovarian cancers is a platinum agent (carboplatin) combined with a taxane (paclitaxel). Regimens and delivery routes (intravenous vs. intraperitoneal) are individualized based on stage, histology, and patient factors.
Germ cell tumors: highly chemosensitive; standard regimens include bleomycin, etoposide, and cisplatin (BEP).
Sex cord–stromal tumors: treatment strategies may include surgery and, for recurrent or advanced hormone-producing tumors, hormonal therapies or chemotherapy depending on subtype and behavior.

Targeted and maintenance therapies:

Molecularly targeted agents have expanded treatment options:
PARP inhibitors (olaparib, niraparib, rucaparib) are effective as maintenance therapy in patients with BRCA-mutated or homologous recombination–deficient ovarian cancers and can improve progression-free survival.
Antiangiogenic agents (bevacizumab) have a role in combination with chemotherapy and as maintenance in selected patients.
Hormone therapy (aromatase inhibitors) may be considered in hormone receptor–positive sex cord–stromal tumors.

Genomic testing for BRCA1/2 and other actionable mutations is recommended for patients with epithelial ovarian cancer to guide therapy and familial risk assessment [NCI], [ACOG].

Role of neoadjuvant chemotherapy

In patients with advanced disease who are poor surgical candidates or when optimal cytoreduction is unlikely at initial surgery, neoadjuvant platinum-based chemotherapy followed by interval cytoreductive surgery is a reasonable alternative and may reduce surgical morbidity while achieving similar survival outcomes in selected trials.

Post-treatment surveillance

Follow-up includes periodic history and physical examination, imaging as clinically indicated, and surveillance of tumor markers (e.g., CA-125) in patients in whom markers were elevated at diagnosis.
Surveillance schedules vary, but close follow-up in the first 2–3 years is important because recurrence risk is highest in that time frame.

Special populations and considerations

Adolescents and young adults

Germ cell tumors and benign teratomas are more common in adolescents. Preservation of fertility is a major concern — many germ cell and early-stage tumors are effectively treated with fertility-sparing surgery and adjuvant chemotherapy when necessary.
Mature cystic teratomas (dermoid cysts) are common and generally benign; they can cause torsion and may warrant surgical removal if symptomatic or large.

Pregnancy

Management balances maternal health and fetal considerations. Many adnexal masses discovered during pregnancy are benign and can be observed; surgery when needed is often performed in the second trimester to reduce obstetric risk. Malignancy during pregnancy is uncommon but requires multidisciplinary care from gynecologic oncology, maternal–fetal medicine, and neonatology.

Postmenopausal patients

Adnexal masses in postmenopausal women carry a higher risk of malignancy. A lower threshold for surgical evaluation and referral to gynecologic oncology applies.

Complications

Ovarian torsion: presents with sudden-onset severe pain; requires urgent surgical intervention.
Rupture: can lead to acute abdomen, hemoperitoneum, and peritonitis; surgical management may be necessary.
Hemorrhage: bleeding into cysts may cause pain and anemia.
Tumor spillage and upstaging: intraoperative cyst rupture in malignant tumors can result in peritoneal spread and affect staging and prognosis.
Adverse effects of chemotherapy: myelosuppression, neuropathy, nephrotoxicity, pulmonary toxicity (bleomycin), and long-term risks.

Genetic counseling and testing

Individuals with epithelial ovarian cancer and those with a relevant family history should be offered genetic counseling and testing for BRCA1/2 and other hereditary cancer syndromes. Identification of pathogenic variants affects surgical decision-making, options for targeted therapy, and screening recommendations for family members.
Prophylactic risk-reducing bilateral salpingo-oophorectomy is recommended for women with high-risk mutations (e.g., BRCA1/2) after childbearing is complete, as it substantially reduces the risk of ovarian and fallopian tube cancer.

Prevention and screening

There is no effective population-wide screening test for ovarian cancer. For the general population, routine screening with CA-125 or transvaginal ultrasound is not recommended because of lack of mortality benefit and risks of false positives and unnecessary surgery.
High-risk women (BRCA carriers) should receive individualized risk-reduction counseling, which may include enhanced surveillance and consideration of prophylactic surgery [ACOG], [NCI].
Primary prevention strategies include oral contraceptive use, which is associated with reduced ovarian cancer risk when used for several years.

Referral and multidisciplinary care

Any patient with an adnexal mass that is complex on imaging, associated with elevated tumor markers suggestive of malignancy, or in whom malignancy cannot be excluded should be referred to a gynecologic oncologist for management.
Multidisciplinary teams that include gynecologic oncology, medical oncology, radiology, pathology, genetic counseling, and fertility specialists provide optimal care for patients with ovarian tumors.

Prognosis

Prognosis varies widely depending on tumor type, stage, histologic grade, and response to therapy.
Early-stage epithelial ovarian cancers and most germ cell tumors have favorable prognoses with appropriate surgical and medical treatment.
Advanced epithelial ovarian carcinoma has a poorer prognosis, although outcomes have improved with advances in cytoreductive surgery, combination chemotherapy, and targeted maintenance therapies.

Practical clinical pathway (summary)

Initial assessment: history, pregnancy test, pelvic exam, transvaginal ultrasound.
If mass is simple, small, and patient is asymptomatic: consider observation with repeat ultrasound.
If mass is complex, large, symptomatic, or tumor markers are concerning: refer to gynecology/gynecologic oncology.
Surgical planning: determine fertility goals, consider laparoscopy for presumed benign disease, refer to gynecologic oncologist for suspected malignancy.
Postoperative care: histopathologic diagnosis directs need for adjuvant therapy, staging completeness determines prognosis and further management.
Genetic testing and counseling: recommended for patients with epithelial ovarian cancer and those with strong family histories.

Key takeaways

Ovarian tumors range from benign functional cysts to aggressive malignancies. Many are asymptomatic, making vigilance important when adnexal masses are identified.
Transvaginal ultrasound is the primary imaging modality, supplemented by tumor marker evaluation and MRI or CT when indicated.
Management is individualized, balancing the risks of malignancy, acute complications, and the patient’s fertility desires.
Referral to specialized gynecologic oncology services is essential when malignancy is suspected to ensure appropriate staging, cytoreductive surgery, and access to systemic and targeted therapies.
Genetic evaluation for hereditary cancer syndromes should be integrated into care for patients with epithelial ovarian cancer.

References and resources

American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin: Management of adnexal masses. [ACOG Practice Bulletin]. https://www.acog.org
National Cancer Institute (NCI) / National Institutes of Health (NIH). Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer. https://www.cancer.gov/types/ovarian
National Institutes of Health — MedlinePlus. Ovarian Cysts. https://medlineplus.gov/ovariancysts.html
Mayo Clinic. Ovarian cyst. https://www.mayoclinic.org/diseases-conditions/ovarian-cyst
Cleveland Clinic. Ovarian cysts and ovarian cancer. https://my.clevelandclinic.org/health/diseases/8585-ovarian-cysts
American Cancer Society. Ovarian Cancer Overview. https://www.cancer.org/cancer/ovarian-cancer.html

(Readers should consult current clinical guidelines and specialist input for patient-specific management decisions. The references listed provide authoritative, up-to-date information from major clinical organizations.)